Semaglutide
Evidence: A/D — Established Human EvidenceMetabolic / Weight Management
Evidence Snapshot
Regulatory Context
FDA-approved under multiple brand names for specific type 2 diabetes and/or chronic weight management indications; off-label or non-indicated uses remain outside FDA approval.
Research Takeaway
Binds and activates the GLP-1 receptor, centrally suppressing appetite and peripherally slowing gastric emptying while enhancing glucose-dependent insulin secretion.
See all 5 evidence claims →Quick Summary
Semaglutide is a GLP-1 receptor agonist FDA-approved under three brand names (Ozempic, Wegovy, Rybelsus) for type 2 diabetes and/or chronic weight management, with the largest published trial program of any current obesity medication.
Mechanism & Research Overview
Binds and activates the GLP-1 receptor; centrally suppresses appetite via hypothalamic POMC/CART stimulation and NPY/AgRP inhibition; peripherally slows gastric emptying and enhances glucose-dependent insulin secretion while lowering glucagon.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Binds and activates the GLP-1 receptor, centrally suppressing appetite and peripherally slowing gastric emptying while enhancing glucose-dependent insulin secretion.
Sources: Spotlight on the Mechanism of Action of Semaglutide; Discovery of the Once-Weekly GLP-1 Analogue Semaglutide
Supported
In the STEP 1 trial, semaglutide 2.4 mg produced substantial weight reduction versus placebo over 68 weeks.
Sources: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Supported
In SUSTAIN-6, semaglutide reduced major adverse cardiovascular events versus placebo in adults with type 2 diabetes at high cardiovascular risk.
Sources: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Supported
Semaglutide is FDA-approved under three brand names (Ozempic, Wegovy, Rybelsus) for specific type 2 diabetes and/or chronic weight-management indications.
Sources: RYBELSUS (semaglutide) FDA Prescribing Information; FDA Approval of Ozempic (Semaglutide), NDA 209637; FDA Approval of Wegovy (Semaglutide), NDA 215256
Supported
Rodent studies showed a thyroid C-cell tumor signal; the FDA label states human relevance is considered low but not excluded.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), per the Rybelsus FDA label.Safety Consideration
Gastrointestinal effects such as nausea, vomiting, and diarrhea are the most common adverse events across the STEP and SUSTAIN trial programs.Safety Consideration
Rodent studies showed a mechanism-based thyroid C-cell tumor signal; the FDA label states human relevance is considered low but not excluded. A dedicated primary rodent toxicology study was not independently opened in this research pass — this reflects the FDA label's own description, not an independently verified toxicology paper.
Research Areas Being Studied
Research areas discussed on this page reflect the Metabolic / Weight Management category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (2021):
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (2016):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) | 2021 | Adults with overweight/obesity | Substantial weight reduction vs. placebo; established the basis for the Wegovy weight-management indication.
| ||
| Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) | 2016 | Adults with type 2 diabetes, high cardiovascular risk | Reduced major adverse cardiovascular events vs. placebo, supporting the CV risk-reduction indication.
|
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Discovery of the Once-Weekly GLP-1 Analogue Semaglutide | 2015 | In vitro receptor assays and animal pharmacology models | Foundational discovery/medicinal-chemistry paper describing semaglutide's design and receptor-binding profile. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| RYBELSUS (semaglutide) FDA Prescribing Information | 2024 | N/A — regulatory labeling document | Approved indications, dosing, and labeled safety information for oral semaglutide (Rybelsus). | ||
| FDA Approval of Wegovy (Semaglutide), NDA 215256 | 2021 | N/A — regulatory approval letter | FDA approved NDA 215256 for Wegovy (semaglutide) injection on June 4, 2021, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults meeting the approved labeling criteria. | ||
| FDA Approval of Ozempic (Semaglutide), NDA 209637 | 2017 | N/A — regulatory approval letter | FDA approved NDA 209637 for Ozempic (semaglutide) injection on December 5, 2017, for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Spotlight on the Mechanism of Action of Semaglutide | 2024 | Mechanistic review | Describes central (hypothalamic POMC/CART, NPY/AgRP) and peripheral (gastric emptying, insulin secretion) mechanisms of action. | ||
| Semaglutide for the treatment of obesity | 2023 | Review article | General review of semaglutide's role in obesity treatment. | ||
| Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 | 2020 | Review of STEP 1-5 trial program | Synthesizes results across the STEP obesity trial program. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Semaglutide is an FDA-approved prescription medicine for specific indications. This page is educational only, does not constitute medical advice, and is not a recommendation to use semaglutide outside a licensed prescriber's care.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-11.
Follow research updates for Semaglutide
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.